Biodexa Pharmaceuticals (BDRX) Prices $5.2M Share Offering at $2.20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Biodexa Announces Pricing of $5.2 Million Underwritten Public Offering
December 19, 2023 8:42 AM ESTBiodexa Pharmaceuticals PLC(Biodexa or the Company)
CARDIFF, United Kingdom, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of an underwritten public offering of units.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the offering.
The underwritten public offering is comprised of (a) 697,614 Class A Units (the Class A Units), with each... More
